India’s cancer care landscape has taken a significant step forward with the launch of Tishtha, a new affordable immunotherapy drug designed to drastically reduce the cost of advanced cancer treatment. Developed as a biosimilar version of nivolumab, Tishtha promises to make life-saving therapy accessible to thousands of patients who were previously unable to afford it.
Immunotherapy has transformed cancer treatment globally, but its high cost has kept it out of reach for many patients in low- and middle-income countries. The introduction of Tishtha marks a critical shift toward affordability without compromising modern treatment standards.
What Is Tishtha and How Does It Work?
Tishtha is a biosimilar of nivolumab, an immune checkpoint inhibitor used in the treatment of multiple cancers. These drugs work by targeting the PD-1 pathway, a mechanism cancer cells exploit to evade the immune system. By blocking this pathway, immunotherapy enables the body’s own immune cells to recognise and attack cancer cells more effectively.
Nivolumab-based therapies are widely used for cancers such as lung cancer, kidney cancer, melanoma, head and neck cancers, and several advanced or recurrent malignancies. Until now, patients in India often had to depend on expensive imported versions, limiting access and continuity of care.
Why Affordability Is a Game Changer
One of the biggest barriers in cancer treatment is cost. Immunotherapy is not a one-time intervention; it is typically administered over several cycles, sometimes spanning months or even years. This results in enormous out-of-pocket expenses for families.
Tishtha has been priced at nearly one-fourth the cost of the original drug, offering immediate financial relief. It is available in two vial strengths—40 mg and 100 mg—allowing doctors to customise doses based on individual patient needs. This also helps minimise drug wastage, further lowering treatment expenses.
For many patients, this price reduction could mean the difference between starting treatment and abandoning it midway due to financial constraints.
Who Stands to Benefit the Most?
India reports nearly 1.5 million new cancer cases every year, with a significant number diagnosed at advanced stages. Immunotherapy has shown promising results in improving survival and quality of life in such cases, but affordability has remained a major challenge.
With the introduction of Tishtha, it is estimated that hundreds of thousands of patients could benefit annually. This includes patients from smaller cities and semi-urban regions, where access to high-end cancer drugs has historically been limited.
Lower costs also increase the likelihood that patients will complete the full course of therapy, which is crucial for achieving optimal outcomes.
Understanding Biosimilars
Biosimilars are not simple generic drugs. They are highly similar versions of complex biologic medicines that are made from living cells. Because biologics involve intricate manufacturing processes, biosimilars undergo rigorous testing to ensure they match the original drug in terms of safety, effectiveness, and quality.
The development of biosimilars requires advanced scientific expertise and strict regulatory oversight. When approved, they offer the same therapeutic benefits as the original biologic but at a significantly reduced cost.
The growing adoption of biosimilars globally has been instrumental in expanding access to advanced treatments for chronic and life-threatening diseases, including cancer.
Legal and Regulatory Significance
The launch of Tishtha also highlights an important shift in how access to essential medicines is viewed in India. Regulatory clearance and judicial decisions surrounding its launch have emphasised public health interest and patient access, balancing innovation with affordability.
This approach underscores a broader recognition that life-saving therapies must not remain inaccessible due to pricing barriers, particularly in countries with a large disease burden and high out-of-pocket healthcare spending.
Impact on Patients and Families
Cancer does not only take a physical toll—it brings immense emotional and financial stress. High treatment costs often force families to sell assets, take loans, or discontinue therapy prematurely.
By lowering the cost of immunotherapy, Tishtha can help reduce this financial toxicity, allowing patients to focus on recovery rather than expenses. Greater affordability may also encourage earlier adoption of immunotherapy when clinically appropriate, rather than reserving it as a last-resort option.
What Doctors Are Watching Closely
While affordability is a major advantage, clinicians stress the importance of continued monitoring of patient outcomes. As with any immunotherapy, responses can vary depending on cancer type, disease stage, and individual biology.
Doctors will closely track real-world data on safety and effectiveness, but early expectations are optimistic given the stringent requirements biosimilars must meet before approval.
A Step Toward More Equitable Cancer Care
The introduction of Tishtha reflects a broader transformation in India’s pharmaceutical sector, which is increasingly focused on developing high-quality, cost-effective biologic medicines. This shift reduces reliance on expensive imports and strengthens domestic capabilities in advanced drug manufacturing.
It also aligns with global efforts to make cancer care more equitable, ensuring that breakthrough therapies are not limited to patients in wealthier nations or higher income brackets.
Looking Ahead
As cancer rates continue to rise, the need for accessible and sustainable treatment solutions becomes more urgent. Affordable immunotherapies like Tishtha may set a precedent for future drug launches, encouraging competition, innovation, and price rationalisation across the oncology market.
If similar models are applied to other high-cost cancer drugs, India could see a meaningful reduction in treatment gaps and improved survival outcomes over the coming decade.
Tishtha represents more than just a new cancer drug—it signals a shift in how advanced cancer care is delivered in India. By dramatically lowering the cost of immunotherapy, it opens doors for patients who were previously excluded due to financial barriers.
As affordability and innovation converge, treatments like Tishtha may play a crucial role in shaping a more inclusive, patient-centric cancer care ecosystem—where access to life-saving therapy is determined by medical need, not financial capacity.
